anzutresgene autoleucel (anzu-cel, IMA203) — Topline data
H1 2027
The Company expects to disclose topline data from the final PFS analysis in the first half of 2027, followed by a BLA submission in 2027.Source filing
IMTX biotech catalysts & pipeline
IMMATICS NV · Data as of 2026-10-27
Upcoming catalysts
anzutresgene autoleucel (anzu-cel, IMA203) — NDA/BLA submission
1H 2027
Findings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in 1H 2027Source filing
IMA401 — Initial data
in 2027
These include combination approaches with ICIs in melanoma and in gynecologic cancers as well as IMA402 in combination with the Company's MAGEA4/8-directed bispecific, IMA401, in lung cancer with first data expected in 2027.Source filing
IMA401 — Clinical data readout
2027
First data from the IMA401/IMA402 combination cohort are expected in 2027.Source filing